- Empowers’ Q3 2019 preliminary unaudited revenue saw a year over year growth of approximately 138%`
- Company’s Q3 preliminary total direct clinic expenses have been reduced by approximately 40% even with the addition of the six Sun Valley clinic locations.
- Earnings results are set to be released on November 14, 2019 at 9:00 am Eastern Time
VANCOUVER B.C. November 7th, 2019 – EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce preliminary unaudited year over year revenue growth of 138% for the three months ended September 30, 2019. The company also decreased total direct clinic expenses by approximately 40%, while adding six new clinics as a result of the Sun Valley clinics acquisition.
The Company also has patient visits in corporate clinics increase by triple digits, with October 2019 patients seen increasing by 336% to 1,847 versus October 2018 with 550 patients seen.
“The Company is starting to feel the positive impact that the Sun Valley clinics acquisition has provided with their strong operational performance in Arizona, in conjunction with continued cost cutting measures with operations in Oregon and Washington State,” said Steven McAuley, CEO of Empower. “We have also been able to integrate key back office, admin, payroll & human resource functions from the Pacific Northwest into the operational controls of Sun Valley, bringing improved productivity to the organization.”
As part of the Company’s continued expansion of our health & wellness clinic model, we have already set up retail CBD product sales in-clinic, and now we have launched expanded physician based services starting with key Arizona clinics.
New Modalities and Services
- Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
- CBD-Cannabis-Supplement Consumption & Coaching Consultation
- Introduction to Alternative Health and Cannabinoid Therapies by a Physician
- Comprehensive Naturopathic Patient Analysis & Consultation
- Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw
- Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
- Spectracell Micronutrient Test & Physician Consultation/Action Plan
Empower plans to release its third quarter results ending September 30th, 2019 on November 14, 2019 at 9:00AM Eastern time.
This news release makes reference to certain non-IFRS measures, including certain industry metrics. These metrics and measures are not recognized measures under IFRS do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. These non-IFRS measures, including the industry measures, are used to provide investors with supplementary measures of our operating performance that may not otherwise be apparent when relying solely on IFRS metrics.
Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Boom Capital Markets
For French inquiries: Remy Scalabrini, Maricom Inc., E: firstname.lastname@example.org, T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.